Find a Clinical Trial

Showing 121 - 130 of 170 Trials

A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT05433142

Population:

Adult

Phase:

I

The purpose of this study is to assess whether an investigational drug called XmAb819 has any effects on Clear Cell Renal Cell Carcinoma, to determine if it is safe and well tolerated, and to determine the dosing schedule. The investigational drug will be given by intravenous (IV – into the vein) infusion over a 2 hour period. This study will also see how the body affects the study drug and how much study drug is in the blood (pharmacokinetics, or “PK”), how the drug affects the tumor and body (pharmacodynamics, or “PD”), and if the body develops antibodies...
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor,RLY‑2608, as a Single Agent in Patients with Advanced SolidTumors and in Combination with Endocrine Therapy +/- aCDK4/6 or CDK4 Inhibitor in Patients with Advanced SolidTumors or Advanced

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT05216432

Population:

Adult

Phase:

I

This research study is designed to learn about the safety of an experimental (investigational) drug called RLY-2608, also called the study drug, when given to individuals who have been diagnosed with metastatic (spread to other areas of the body) or unresectable (cannot be removed surgically) cancers and have at least one mutation in a gene called PIK3CA. “Investigational” means that it is not yet known if this drug helps patients, has not been approved by the Food and Drug Administration (FDA) or any other regulatory agency, and is not available for sale as a marketed product...
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06859762

Population:

Adult

Phase:

I

The main purpose of this study is to evaluate the safety and effectiveness of the study drug, YL217, in different solid tumor types. We also want to learn: ● The dosage of YL217 that can be safely given to humans ● What effect (good or bad) YL217 has on your cancer ● What happens to YL217 once it is in your body (so called pharmacokinetics; PK) ● What YL217 does to your body MediLink Therapeutics has begun a study of an investigational drug (also known as the “study drug”) called YL217 as a possible treatment for CDH17 expressed solid tumors. CDH17 is a type of protein found on...
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT07082920

Population:

Adult

Phase:

I

The purpose of this study is to find a safe dose of investigational study drug, JNJ- 95298177 when given in combination with investigational drug, JNJ-78278343 in patients with prostate cancer. JNJ-78278343 and JNJ-95298177 are not approved by the United States Food and Drug Administration (FDA). The sponsor, Janssen Research & Development, provides the investigational study treatment, called “JNJ-78278343 and JNJ-95298177”. This is the first time that JNJ-78278343 is being used in combination with JNJ-95298177. Are you Eligible? (Inclusion Criteria) At the time of informed...
A Phase 1, First-in-Human, multicenter, open-label trial ofDS9051b in participants with advanced or metastaticadrenocortical carcinoma (ACC) and metastatic castrationresistantprostate cancer (mCRPC)

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT07189403

Population:

Adult

Phase:

I

he purpose of this trial is to learn more about an investigational drug called DS9051b. DS9051b is an investigational drug that is not Food and Drug Administration (FDA) approved for your disease. This is a first in human study. It is being studied to see if it is safe, and if your disease improves while taking it. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be able to swallow the study drug - Must not have known gastrointestinal disease or procedure that may interfere with absorption of the study drug
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advance Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06589596

Population:

Adult

Phase:

I

The purpose of this study is to test if the study drug (BGB-58067) alone and the study drug combinations including tislelizumab and chemotherapy (carboplatin, cisplatin, pemetrexed, paclitaxel, nab-paclitaxel, gemcitabine, fluorouracil, leucovorin, irinotecan, and oxaliplatin) are safe and tolerable, test how your body processes the study drug/the study drug combinations, find the safest and most appropriate dose(s) and test if it/they work in patients with advanced solid tumor who have methylthioadenosine phosphorylase (MTAP) deficiency, including those with a loss of MTAP or no MTAP...
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT05176483

Population:

Adult

Phase:

I

The purpose of this study is to evaluate the efficacy of the study drug, XL092 alone and/or in combination of other study drugs such as with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed dose combination as a potential anticancer therapy to treat people with locally advanced or metastatic cancers including advanced renal cell cancer, castration-resistant prostate cancer, bladder cancer, liver cancer, lung cancer, colon cancer, head and neck cancer. Nivolumab has been approved as single agent for the treatment of melanoma, lung cancer, and bladder cancer and in...
A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects with Advanced Urothelial and Squamous Cell Carcinomas

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT07217171

Population:

Adult

Phase:

I

The purpose of this study is to learn about the safety of the study drug, EVOLVE104, to find out if it is effective against several different kinds of cancer, and to find the best dose for treating those kinds of cancer. Some of the tumors that EVOLVE104 might work against include some cancers of the bladder, lungs, esophagus, skin, cervix, anus and genitals. EVOLVE104 is a type of immunotherapy. Immunotherapy is a type of cancer treatment that utilizes the body's own immune system to combat cancer cells. EVOLVE104 sticks to a specific type of immune cell (called T cells) and to several...
A Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy ofONC-783 in Advanced Solid Tumors

Principal Investigator:

Aiwu R He, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07408258

Population:

Adult

Phase:

I

This research study is a first-in-human Phase 1 study. The study tests the effects of study drug, ONC-783, in the treatment of advanced or metastatic colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer. The most important measurement for the study is to see whether ONC-783 is safe and tolerable, how it is processed in the blood/body and whether it could slow down tumor growth. ONC-783 is an investigational drug being developed as an anti-tumor treatment. ONC-783 is a bispecific antibody drug, which means it may bring immune cells (that protect the body against diseases) and...
A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) with oral Etoposide Administration in Children, Adolescents, and Young Adults with Progressive Diffuse Midline Glioma (DMG)

Principal Investigator:

Stergios Zacharoulis, MD

Contact Number:

212-342-5162

NCT Number:

NCT05762419

Population:

Pediatrics/Adult

Phase:

I

Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY® microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages